OBJECTIVE: Intravenous (IV) levetiracetam (LEV) is approved for use in patients older than 16 years and may be useful in critically ill children, although there is little data available regarding pharmacokinetics. We aim to investigate the safety, an appropriate dosing, and efficacy of IV LEV in critically ill children. DESIGN: We describe a cohort of critically ill children who received IV LEV for status epilepticus, including refractory or nonconvulsive status, or acute repetitive seizures. RESULTS: There were no acute adverse effects noted. Children had temporary cessation of ongoing refractory status epilepticus, termination of ongoing nonconvulsive status epilepticus, cessation of acute repetitive seizures, or reduction in epileptiform discharges with clinical correlate. CONCLUSIONS: IV LEV was effective in terminating status epilepticus or acute repetitive seizures and well tolerated in critically ill children. Further study is needed to elucidate the role of IV LEV in critically ill children.
OBJECTIVE: Intravenous (IV) levetiracetam (LEV) is approved for use in patients older than 16 years and may be useful in critically ill children, although there is little data available regarding pharmacokinetics. We aim to investigate the safety, an appropriate dosing, and efficacy of IV LEV in critically ill children. DESIGN: We describe a cohort of critically ill children who received IV LEV for status epilepticus, including refractory or nonconvulsive status, or acute repetitive seizures. RESULTS: There were no acute adverse effects noted. Children had temporary cessation of ongoing refractory status epilepticus, termination of ongoing nonconvulsive status epilepticus, cessation of acute repetitive seizures, or reduction in epileptiform discharges with clinical correlate. CONCLUSIONS: IV LEV was effective in terminating status epilepticus or acute repetitive seizures and well tolerated in critically ill children. Further study is needed to elucidate the role of IV LEV in critically ill children.
Authors: S Knake; J Gruener; K Hattemer; K M Klein; S Bauer; W H Oertel; H M Hamer; F Rosenow Journal: J Neurol Neurosurg Psychiatry Date: 2007-09-26 Impact factor: 10.154
Authors: Andrey M Mazarati; Roger Baldwin; Henrik Klitgaard; Alain Matagne; Claude G Wasterlain Journal: Epilepsy Res Date: 2004-02 Impact factor: 3.045
Authors: Tracy Glauser; Shlomo Shinnar; David Gloss; Brian Alldredge; Ravindra Arya; Jacquelyn Bainbridge; Mary Bare; Thomas Bleck; W Edwin Dodson; Lisa Garrity; Andy Jagoda; Daniel Lowenstein; John Pellock; James Riviello; Edward Sloan; David M Treiman Journal: Epilepsy Curr Date: 2016 Jan-Feb Impact factor: 7.500
Authors: Nicholas S Abend; Ana M Gutierrez-Colina; Heather M Monk; Dennis J Dlugos; Robert R Clancy Journal: J Child Neurol Date: 2011-01-13 Impact factor: 1.987
Authors: Gretchen M Brophy; Rodney Bell; Jan Claassen; Brian Alldredge; Thomas P Bleck; Tracy Glauser; Suzette M Laroche; James J Riviello; Lori Shutter; Michael R Sperling; David M Treiman; Paul M Vespa Journal: Neurocrit Care Date: 2012-08 Impact factor: 3.210
Authors: Nicholas S Abend; David Bearden; Ingo Helbig; Jennifer McGuire; Sona Narula; Jessica A Panzer; Alexis Topjian; Dennis J Dlugos Journal: Semin Pediatr Neurol Date: 2014-12-12 Impact factor: 3.042
Authors: Abhishek G Sathe; Usha Mishra; Vijay Ivaturi; Richard C Brundage; James C Cloyd; Jordan J Elm; James M Chamberlain; Robert Silbergleit; Jaideep Kapur; Daniel H Lowenstein; Shlomo Shinnar; Hannah R Cock; Nathan B Fountain; Lynn Babcock; Lisa D Coles Journal: J Clin Pharmacol Date: 2021-01-12 Impact factor: 2.860